文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

COVID-19 住院患者 ICU 与非 ICU 治疗至出院后 2 年的长期健康结局:纵向队列研究(CO-FLOW)

Long-term health outcomes of COVID-19 in ICU- and non-ICU-treated patients up to 2 years after hospitalization: a longitudinal cohort study (CO-FLOW).
PubMed 文献 · J Intensive Care · 2024-11-08
一句话结论COVID-19 住院幸存者出院 2 年时 73%(322/443)未完全康复,ICU 治疗者神经认知、心理健康与复工恢复更慢,女性及既往肺病为不良结局主要危险因素。

CO-FLOW 多中心前瞻性队列研究随访 650 例 COVID-19 住院幸存者(中位年龄 60.0 岁,69% 男性,42% 接受 ICU 治疗),于出院后 3、6、12、24 个月评估患者报告结局及客观认知与体能测试。总体结局随时间改善,但 2 年时 73%(322/443)未完全康复,记忆问题 55%、注意力问题 52%、呼吸困难 51%、睡眠质量差 61%、疲劳 51%、认知失误 23%、30% 未完全复工,客观体能恢复总体良好。ICU 与非 ICU 治疗者 2 年时多数结局相当,但 ICU 治疗者神经认知症状、心理健康及复工恢复更慢、体能改善更多;女性与既往肺病为结局较差的主要危险因素。作者认为长期 COVID-19 善后需按个体残余需求定制,并需随访监测进一步恢复。

要点

  • 出院 2 年时 73%(322/443)COVID-19 住院幸存者未完全康复,记忆问题 55%(274/443)、注意力问题 52%(259/443)、呼吸困难 51%(251/493)为最常见残留症状。
  • 2 年时 61%(259/427)睡眠质量差、51%(222/433)疲劳、23%(102/438)认知失误、30%(65/216)未完全复工。
  • ICU 治疗者与非 ICU 治疗者 2 年时多数结局相当,但 ICU 治疗者神经认知症状、心理健康与复工恢复更慢,体能结局改善更多。
  • 女性与/或既往肺病是 COVID-19 后突出健康问题的主要危险因素。
  • 尽管客观体能恢复总体良好,神经认知主诉、呼吸困难、疲劳与睡眠质量受损持续存在,作者认为长期善后需按个体残余需求定制并随访监测。

适用人群与场景

  • CO-FLOW 多中心前瞻性队列纳入的 COVID-19 住院成年幸存者,共 650 例,中位年龄 60.0 岁(IQR 53.0-67.0),449/650(69%)为男性,273/650(42%)接受过 ICU 治疗。
  • 于出院后 3、6、12、24 个月随访,评估患者报告结局(康复、症状、疲劳、心理健康、睡眠质量、复工、健康相关生活质量)及客观认知与体能测试,并收集常规随访数据。

研究设计与关键结果

  • 研究类型为 CO-FLOW 多中心前瞻性队列研究,纳入 650 例 COVID-19 住院幸存者,273/650(42%)接受 ICU 治疗,随访至出院后 24 个月。
  • 总体结局随时间改善,但 2 年时 73%(322/443)未完全康复;最常见症状为记忆问题 274/443(55%)、注意力问题 259/443(52%)、呼吸困难 251/493(51%)。
  • 2 年时 61%(259/427)睡眠质量差、51%(222/433)疲劳、23%(102/438)认知失误、30%(65/216)未完全复工;客观体能测量显示总体恢复良好。
  • 2 年时 ICU 与非 ICU 治疗者多数结局相当,但 ICU 治疗者神经认知症状、心理健康结局与复工恢复趋于更慢,体能结局改善更多。
  • 女性与/或既往肺病为 COVID-19 后结局较差的主要危险因素。

证据类型、等级与局限

  • 证据类型:多中心前瞻性队列研究(CO-FLOW),试验注册号 NL8710,注册日期 2020 年 6 月 12 日。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,长期 COVID-19 善后需按个体残余需求定制。
  • 作者认为,需随访以监测进一步恢复。
  • ICU 治疗者神经认知症状、心理健康与复工恢复更慢,女性及既往肺病患者结局更差,提示随访中应关注这些人群的残余问题。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Many patients hospitalized for COVID-19 experience long-term health problems, but comprehensive longitudinal data up to 2 years remain limited. We aimed to (1) assess 2-year trajectories of health outcomes, including comparison between intensive care unit (ICU) treated and non-ICU-treated patients, and (2) identify risk factors for prominent health problems post-hospitalization for COVID-19.

METHODS: The CO-FLOW multicenter prospective cohort study followed adults hospitalized for COVID-19 at 3, 6, 12, and 24 months post-discharge. Measurements included patient-reported outcomes (a.o., recovery, symptoms, fatigue, mental health, sleep quality, return to work, health-related quality of life [HRQoL]), and objective cognitive and physical tests. Additionally, routine follow-up data were collected.

RESULTS: 650 patients (median age 60.0 [IQR 53.0-67.0] years; 449/650 [69%] male) surviving hospitalization for COVID-19 were included, of whom 273/650 (42%) received ICU treatment. Overall, outcomes improved over time. Nonetheless, 73% (322/443) of patients had not completely recovered from COVID-19, with memory problems (274/443; 55%), concentration problems (259/443; 52%), and dyspnea (251/493; 51%) among most frequently reported symptoms at 2 years. Moreover, 61% (259/427) had poor sleep quality, 51% (222/433) fatigue, 23% (102/438) cognitive failures, and 30% (65/216) did not fully return to work. Objective outcome measures showed generally good physical recovery. Most outcomes were comparable between ICU- and non-ICU-treated patients at 2 years. However, ICU-treated patients tended to show slower recovery in neurocognitive symptoms, mental health outcomes, and resuming work than non-ICU-treated patients, while showing more improvements in physical outcomes. Particularly, female sex and/or pre-existing pulmonary disease were major risk factors for poorer outcomes.

CONCLUSIONS: 73% (322/443) of patients had not completely recovered from COVID-19 by 2 years. Despite good physical recovery, long-term neurocognitive complaints, dyspnea, fatigue, and impaired sleep quality persisted. ICU-treated patients showed slower recovery in neurocognitive and mental health outcomes and resumption of work. Tailoring long-term COVID-19 aftercare to individual residual needs is essential. Follow-up is required to monitor further recovery.

TRIAL REGISTRATION: NL8710, registration date 12-06-2020.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Berentschot JC, Bek LM, Heijenbrok-Kal MH, et al. Long-term health outcomes of COVID-19 in ICU- and non-ICU-treated patients up to 2 years after hospitalization: a longitudinal cohort study (CO-FLOW). J Intensive Care. 2024. PMID: 39516956. doi:10.1186/s40560-024-00748-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。